| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $105.71 | $113.53B | N/A |
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895
Oct 28, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
0
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
https://www.fool.com/investing/2019/10/28/wall-street-has-given-up-on-these-3-stocks-and-tha.aspx?source=iedfolrf0000001
Oct 28, 2019 - Value investing is all about being willing to buy solid companies when the market throws a sale.
0
Eli Lilly and Company (LLY) Q3 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/10/24/eli-lilly-and-company-lly-q3-2019-earnings-call-tr.aspx?source=iedfolrf0000001
Oct 24, 2019 - LLY earnings call for the period ending September 30, 2019.
0
Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4298376-eli-lilly-company-lly-ceo-dave-ricks-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Oct 23, 2019 - Eli Lilly and Company (NYSE:LLY) Q3 2019 Earnings Conference Call October 23, 2019 09:00 ET Company Participants Kevin Hern - VP IR Dave Ricks - Chairman & CEO Josh Smiley - CFO Dan Skovronsky - P
0
Why Eli Lilly Stock Fell Despite Its Solid Q3 Earnings Beat
https://www.fool.com/investing/2019/10/23/why-eli-lilly-stock-fell-despite-its-solid-q3-earn.aspx?source=iedfolrf0000001
Oct 23, 2019 - The big drugmaker seemingly did what it needed to do in Q3. Except for one thing.
0
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
http://www.zacks.com/stock/news/577360/drug-biotech-stock-q3-earnings-on-oct-23-lly-alxn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-577360
Oct 22, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
0
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
http://www.zacks.com/stock/news/569619/lillys-pancreatic-cancer-candidate-fails-in-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569619
Oct 17, 2019 - Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
0
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
http://www.zacks.com/stock/news/569574/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-569574
Oct 17, 2019 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
0
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
http://www.zacks.com/stock/news/567502/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-567502
Oct 16, 2019 - Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
3 Dividend-Paying Pharma Stocks to Buy Now
https://www.fool.com/investing/2019/10/15/3-dividend-paying-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001
Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
0